nach oben

Erschienen in:

09.12.2019 | Original articles

Dynamic thiol/disulphide homeostasis in patients with hypertrophic cardiomyopathy

verfasst von: Munevver Sari, MD, Unal Erkorkmaz, MD, Hayrullah Yazar, MD, Ibrahim Kocayigit, MD, Bahadir Omar, MD, Elnur Alizade, MD, M. N. Murat Aksoy, MD, Abdulkadir Uslu, MD, Gozde Cakirsoy Cakar, MD, Selcuk Pala, MD

Erschienen in: Herz | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

In addition to the genetic complexity of hypertrophic cardiomyopathy (HCM), there must be other disease-modifying factors that contribute to its highly variable clinical and phenotypic expression. The authors aimed to investigate serum thiol/disulphide homeostasis as a proxy for oxidative stress using a novel automated assay in patients with HCM.

Methods

This cross-sectional study was conducted on 119 patients with HCM and 52 without HCM. The methods used to measure dynamic thiol/disulphide homeostasis as calorimetric and duplex quantities were developed in 2014.

Results

Median serum native thiol levels were significantly lower in patients with HCM than in those without (312.5 μmol/L [285–370 μmol/L] vs 421 μmol/L [349–469.5 μmol/L]; p < 0.001). Serum total thiol levels and disulphide levels were considerably lower than those in the control group ([844.68 ± 195.99 μmol/L vs 1158.92 ± 243.97 μmol/L; p < 0.001], [259.13 ± 65.66 μmol/L vs 375.02 ± 79.99 μmol/L; p < 0.001], respectively). Serum disulphide/native thiol ratios and disulphide/total thiol ratios were significantly lower in HCM patients than in controls (0.80 ± 0.09 vs 0.92 ± 0.05; p < 0.001 and 0.31 [0.30–0.32] vs 0.32 [0.32–0.33]; p < 0.001). Finally, reduced thiol ratios were higher and oxidized thiol ratios were significantly lower in patients with HCM than in controls.

Conclusions

Despite the fact that antioxidant capacity was impaired, the extracellular environment remained in a reducing state by keeping serum disulphide/native thiol ratios low. Therefore, the authors speculate that HCM may behave similarly to tumours with respect to serum thiol-disulphide levels.

Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F et al (2014) ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779. https://doi.org/10.1093/eurheartj/ehu284CrossRefPubMed

Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I (2018) Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation 138(14):1387–1398. https://doi.org/10.1161/CIRCULATIONAHA.117.033200CrossRefPubMedPubMedCentral

Frey N, Luedde M, Katus HA (2011) Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 9(2):91–100. https://doi.org/10.1038/nrcardio.2011.159CrossRefPubMed

Erel O, Neselioglu S (2014) A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 47(18):326–332. https://doi.org/10.1016/j.clinbiochem.2014.09.026CrossRefPubMed

Altiparmak IH, Erkus ME, Sezen H, Demirbag R, Kaya Z, Sezen Y, Gunebakmaz O, Asoglu R, Besli F, Neselioglu S, Erel O (2016) Evaluation of thiol levels, thiol/disulfide homeostasis and their relation with inflammation in cardiac syndrome X. Coron Artery Dis 27(4):295–301. https://doi.org/10.1097/MCA.0000000000000362CrossRefPubMed

Altıparmak IH, Erkuş ME, Sezen H, Demirbag R, Gunebakmaz O, Kaya Z, Sezen Y, Asoglu R, Dedeoglu IH, Neselioglu S, Erel O (2016) The relation of serum thiol levels and thiol/disulphide homeostasis with the severity of coronary artery disease. Kardiol Pol 74(11):1346–1353. https://doi.org/10.5603/KP.a2016.0085CrossRefPubMed

Kızıltunç E, Gök M, Kundi H, Çetin M, Topçuoğlu C, Gülkan B, Çiçekçioğlu H, Örnek E (2016) Plasma thiols and thiol-disulfide homeostasis in patients with isolated coronary artery ectasia. Atherosclerosis 253:209–213. https://doi.org/10.1016/j.atherosclerosis.2016.07.904CrossRefPubMed

Kundi H, Ates I, Kiziltunc E, Cetin M, Cicekcioglu H, Neselioglu S, Erel O, Ornek E (2015) A novel oxidative stress marker in acute myocardial infarction; thiol/disulphide homeostasis. Am J Emerg Med 33(11):1567–1571. https://doi.org/10.1016/j.ajem.2015.06.016CrossRefPubMed

Ergin M, Caliskanturk M, Senat A, Akturk O, Erel O (2016) Disulfide stress in carbon monoxide poisoning. Clin Biochem 49(16/17):1243–1247. https://doi.org/10.1016/j.clinbiochem.2016.07.019CrossRefPubMed

10.

Topuz M, Kaplan M, Akkus O, Sen O, Yunsel HD, Allahverdiyev S, Erel O, Koc M, Gur M (2016) The prognostic importance of thiol/disulfide homeostasis in patients with acute pulmonary thromboembolism. Am J Emerg Med 34(12):2315–2319. https://doi.org/10.1016/j.ajem.2016.08.039CrossRefPubMed

11.

Dinc ME, Ozdemir C, Ayan NN, Bozan N, Ulusoy S, Koca C, Erel O (2017) Thiol/disulfide homeostasis as a novel indicator of oxidative stress in obstructive sleep apnea patients. Laryngoscope 127(7):244–250. https://doi.org/10.1002/lary.26444CrossRef

12.

Ates I, Ozkayar N, Inan B, Yilmaz FM, Topcuoglu C, Neselioglu S, Erel O, Dede F, Yilmaz N (2016) Dynamic thiol/disulphide homeostasis in patients with newly diagnosed primary hypertension. J Am Soc Hypertens 10(2):159–166. https://doi.org/10.1016/j.jash.2015.12.008CrossRefPubMed

13.

Ergin M, Aydin C, Yurt EF, Cakir B, Erel O (2018) The variation of disulfides in the progression of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. https://doi.org/10.1055/s-0044-100376CrossRefPubMed

14.

Bektas H, Vural G, Gumusyayla S, Deniz O, Alisik M, Erel O (2016) Dynamic thiol–disulfide homeostasis in acute ischemic stroke patients. Acta Neurol Belg 116(4):489–494. https://doi.org/10.1007/s13760-016-0598-1CrossRefPubMed

15.

Eroglu S, Haskul I, Aziz V, Yurtcu E, Karatas F, Neselioglu S, Erel O (2017) Dynamic thiol/disulphide homeostasis in patients with uterine myoma. Eur J Obstet Gynecol Reprod Biol 216:24–26. https://doi.org/10.1016/j.ejogrb.2017.06.045CrossRefPubMed

16.

Guney T, Kanat IF, Alkan A, Alisik M, Akinci S, Silay K, Neselioglu S, Dilek I, Erel O (2017) Assessment of serum thiol/disulfide homeostasis in multiple myeloma patients by a new method. Redox Rep 22(6):246–251. https://doi.org/10.1080/13510002.2016.1180100CrossRefPubMed

17.

Hanikoglu F, Hanikoglu A, Kucuksayan E, Alisik M, Gocener AA, Erel O, Baykara M, Cuoghi A, Tomasi A, Ozben T (2016) Dynamic thiol/disulphide homeostasis before and after radical prostatectomy in patients with prostate cancer. Free Radic Res 50(1):79–84. https://doi.org/10.1080/10715762.2016.1235787CrossRef

18.

Dirican N, Dirican A, Sen O, Aynali A, Atalay S, Bircan HA, Oztürk O, Erdogan S, Cakir M, Akkaya A (2016) Thiol/disulfide homeostasis: a prognostic biomarker for patients with advanced non-small cell lung cancer? Redox Rep 21(5):197–203. https://doi.org/10.1179/1351000215Y.0000000027CrossRefPubMedPubMedCentral

19.

Lin CS, Liu CY, Sun YL, Chang LC, Chiu YT, Huang SY, Lin JH, Yang PC, Chu R, Huang MC, Mao SJ (1997) Alteration of endogenous antioxidant enzymes in naturally occurring hypertrophic cardiomyopathy. Biochem Mol Biol Int 43(6):1253–1263PubMed

20.

Christiansen LB, Dela F, Koch J, Hansen CN, Leifsson PS, Yokota T (2015) Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 308(10):1237–1247. https://doi.org/10.1152/ajpheart.00727.2014CrossRef

21.

Dimitrow PP, Undas A, Wolkow P, Tracz W, Dubiel JS (2009) Enhanced oxidative stress in hypertrophic cardiomyopathy. Pharmacol Rep 61(3):491–495CrossRef

22.

Nakamura K, Kusano KF, Matsubara H, Nakamura Y, Miura A, Nishii N, Banba K, Nagase S, Miyaji K, Morita H, Saito H, Emori T, Ohe T (2005) Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 11(2):117–123CrossRef

23.

Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J, Willerson JT, Betocchi S, Wickline SA, Efimov IR, Marian AJ (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119(10):1398–1407. https://doi.org/10.1161/CIRCULATIONAHA.108.790501CrossRefPubMedPubMedCentral

24.

Marian AJ, Senthil V, Chen SN, Lombardi R (2006) Antifibrotic effects of antioxidant N‑acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 47(4):827–834. https://doi.org/10.1016/j.jacc.2005.10.041CrossRefPubMedPubMedCentral

25.

Wilder T, Ryba DM, Wieczorek DF, Wolska BM, Solaro RJ (2015) N‑acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 309(10):1720–1730. https://doi.org/10.1152/ajpheart.00339.2015CrossRef

26.

Marian AJ, Tan Y, Li L, Chang J, Syrris P, Hessabi M, Rahbar MH, Willerson JT, Cheong BY, Liu CY, Kleiman NS, Bluemke DA, Nagueh SF (2018) Hypertrophy regression with N‑acetylcysteine in hypertrophic cardiomyopathy (HALT-HCM): a randomized, placebo-controlled, double-blind pilot study. Circ Res 122(8):1109–1118. https://doi.org/10.1161/CIRCRESAHA.117.312647CrossRefPubMedPubMedCentral

27.

Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT, Roberts R, Marian AJ (2005) Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 97(3):285–292. https://doi.org/10.1161/01.RES.0000177090.07296.acCrossRefPubMedPubMedCentral

28.

Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ (2001) Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104(3):317–324CrossRef

29.

Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121(7):749–770. https://doi.org/10.1161/CIRCRESAHA.117.311059CrossRefPubMedPubMedCentral

30.

Sugden PH, Clerk A (2006) Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes. Antioxid Redox Signal 8(11/12):2111–2124. https://doi.org/10.1089/ars.2006.8.2111CrossRefPubMed

31.

Kirlin WG, Cai J, Thompson SA, Diaz D, Kavanagh TJ, Jones DP (1999) Glutathione redox potential in response to differentiation and enzyme inducers. Free Radic Biol Med 27(11/12):1208–1218. https://doi.org/10.1016/S0891-5849(99)00145-8CrossRefPubMed

32.

Jonas CR, Ziegler TR, Gu LH, Jones DP (2002) Extracellular thiol/disulfide redox state affects proliferation rate in a human colon carcinoma (Caco2) cell line. Free Radic Biol Med 33(11):1499–1506CrossRef

33.

Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS (2003) H₂O₂ regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 35(6):615–621CrossRef

34.

Lang CA, Mills BJ, Mastropaolo W, Liu MC (2000) Blood glutathione decreases in chronic diseases. J Lab Clin Med 135(5):402–405. https://doi.org/10.1067/mlc.2000.105977CrossRefPubMed

35.

Liu RM, Liu Y, Forman HJ, Olman M, Tarpey MM (2004) Glutathione regulates transforming growth factor-β-stimulated collagen production in fibroblasts. Am J Physiol Lung Cell Mol Physiol 286:L121. https://doi.org/10.1152/ajplung.00231.2003CrossRefPubMed

Titel: Dynamic thiol/disulphide homeostasis in patients with hypertrophic cardiomyopathy
verfasst von: Munevver Sari, MD
Unal Erkorkmaz, MD
Hayrullah Yazar, MD
Ibrahim Kocayigit, MD
Bahadir Omar, MD
Elnur Alizade, MD
M. N. Murat Aksoy, MD
Abdulkadir Uslu, MD
Gozde Cakirsoy Cakar, MD
Selcuk Pala, MD
Publikationsdatum: 09.12.2019
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 2/2021
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-04853-7

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Dynamic thiol/disulphide homeostasis in patients with hypertrophic cardiomyopathy